Investment Thesis
ArriVent is a pre-revenue biotech company with no reported revenue and operating losses of $46.1M, burning approximately $41.9M in cash per period. While the balance sheet is fundamentally sound with $62.1M cash and minimal debt, the current cash runway is limited to approximately 1.5 periods at present burn rates, creating existential risk without near-term revenue generation or capital infusion.
Strengths
- Strong balance sheet with $324.0M stockholders' equity and only $25.3M in liabilities
- Substantial cash reserves of $62.1M providing operational cushion
- Minimal debt burden with 0.00x debt-to-equity ratio and no long-term debt obligations
- Exceptional liquidity position with 13.95x current ratio enabling short-term solvency
Risks
- Pre-revenue status with no demonstrated commercialized products or revenue generation
- Rapid cash burn of $41.9M per period creates critical runway pressure within 1.5 periods
- Negative operating income of $46.1M and negative net income of $43.3M indicate unsustainable cost structure
- No insider buying activity in last 90 days suggests lack of confidence from insiders
- Deteriorating EPS of -0.96 per share reflects value destruction and capital consumption
Key Metrics to Watch
- Operating cash burn rate and months of cash runway remaining
- Milestone achievements in clinical development pipeline and regulatory progress
- Revenue initiation events or commercial partnerships validating business model
Financial Metrics
Revenue
N/A
Net Income
-43.3M
EPS (Diluted)
$-0.96
Free Cash Flow
-41.9M
Total Assets
349.3M
Cash
62.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-13.4%
ROA
-12.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
13.95x
Quick Ratio
13.95x
Debt/Equity
0.00x
Debt/Assets
7.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T07:51:07.837444 |
Data as of: 2026-03-31 |
Powered by Claude AI